

**APPENDIX A - SPECIFICATION/CLAIM AMENDMENTS
INCLUDING NOTATIONS TO INDICATE CHANGES MADE**

Serial No.: 09/727,739

Confirmation No.: 4181

Docket No.: 255.00040101

Amendments to the following are indicated by underlining what has been added and bracketing what has been deleted. Additionally, all amendments have been shaded.

In the Claims

For convenience, all pending claims are shown below:

1. An isolated or purified somatostatin polypeptide comprising a polypeptide selected from the group consisting of:
 - (a) a polypeptide comprising SEQ ID NO:15;
 - (b) a subunit of the polypeptide of (a) comprising SEQ ID NO:16 and at least 7 contiguous amino acids from SEQ ID NO:17;
 - (c) an analog of the polypeptide of (a) that has an amino acid sequence at least about 85% identical to SEQ ID NO:15; and
 - (d) an analog of the subunit of (b) having an amino acid sequence at least about 90% identical to the amino acid sequence of the subunit;wherein the somatostatin polypeptide binds to a somatostatin receptor.
2. The somatostatin polypeptide of claim 1, wherein the somatostatin polypeptide comprises at least one amino acid sequence selected from the group consisting of SEQ ID NOs:2, 16, 17, 18, and 19.
3. (Twice Amended) ~~[A] An isolated or purified~~ polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs:15, 17, ~~[18]~~ and 19.
4. (Twice Amended) ~~[A] An isolated or purified~~ polynucleotide comprising at least one nucleotide sequence that encodes at least one somatostatin polypeptide of claim 1.
5. The polynucleotide of claim 4 comprising SEQ ID NO:20.

Amendment and Response under 37 C.F.R. §1.116- Appendix A***A - 2******Applicant(s): Sheridan et al.******Serial No.: 09/727,739******Confirmation No.: 4181******Filed: December 1, 2000******For: SOMATOSTATINS AND METHODS***

6. A polynucleotide that is substantially complementary to the polynucleotide of claim 4.
7. (Canceled)
8. (Canceled)
9. (Canceled)
10. (Canceled)
11. (Canceled)
12. A fusion polypeptide comprising an N-terminal somatostatin region comprising at least one first amino acid sequence comprising a somatostatin polypeptide of claim 1 covalently linked to a C-terminal region comprising a second amino acid sequence.
13. The fusion polypeptide of claim 12 wherein the second amino acid sequence encodes a bioactive moiety.
14. The fusion polypeptide of claim 12 wherein the first amino acid sequence comprises at least one amino acid sequence selected from the group consisting of NOs: 15, 16, 17, 18, and 19.
15. The fusion polypeptide of claim 13 wherein the first amino acid sequence comprises SEQ ID NO:18.